Abstract: Provided herein are ruthenium complexes of Formula I, and processes of preparation thereof. Also provided are methods of their use as a metathesis catalyst.

Abstract: Compounds of the general formula are disclosed with activity towards treating diseases related to inflammation, such as cancer, neurodegenerative and cardiovascular diseases. Pharmaceutical compositions and methods of use are also disclosed.

Abstract: Methods and compositions for the treatment and prevention of posterior capsular opacification are provided. The method comprises administering a therapeutically effective amount of a combretastatin to a subject suffering from or at risk of developing posterior capsule opacification.

Abstract: Compounds of the general formula are disclosed with activity towards treating diseases related to inflammation, such as cancer, neurodegenerative and cardiovascular diseases. Pharmaceutical compositions and methods of use are also described.

Abstract: Stilbene compounds for the prevention and treatment of colon cancer or colon inflammation and methods of using same are provided.

Abstract: Processes for synthesizing resveratrol-based oligomers are provided. In addition, resveratrol-based oligomer compounds free of plant extract are provided.

Abstract: The invention relates to a compound of the formula (I) in which: R1, R2 and R3 are independently a methoxy group optionally substituted by one or more fluorine atoms; R4 is a hydrogen atom; R5 and R6 are identical and each represent a hydrogen or fluorine atom; A is a cycle selected from the group including aryl and heteroaryl groups, wherein said groups can be substituted.

Abstract: Compounds of the general formula are disclosed with activity towards treating diseases related to inflammation, such as cancer, neurodegenerative and cardiovascular diseases. Pharmaceutical compositions and methods of use are also described.

Abstract: Combretastatin A-4 has been previously selected for pre-clinical development as antineoplastic agent. However, it is essentially insoluble in water. New water soluble derivatives of combretastatin A-4 and its qualified analogs have been discovered and synthesized through a multistage process using other derivatives of combretastatin A-4 as intermediates. These water soluble derivatives are herein denominated as “Combretastatin A-4 Prodrugs”.

Abstract: Compositions for the inhibition of the formation of new vaculature by angiogenesis are provided as in compounds which are salts comprising as an acidic component a compound of formula (1) wherein: R1, R2 and R3 are each independently alkyl, R4 is alkoxy, haloalkoxy, alkyl, haloalkyl, alkenyl, alkynyl, alkylthio, alkylsulphinyl, alkylsulphonyl, hydroxy or halo, R5 is hydrogen, alkoxy, alkyl, alkylthio, hydroxy, phosphate or halo, and, as the basic component, a compound selected from the group consisting of (2) a compound of formula (2) wherein R6 is hydrogen or alkyl R7 is alkyl, alkylamino, dialkylamino, nitroamino, hydrazine, mercapto or alkylthio X is CH2, CH2CH2, CH2S, CH2CH2S Y is NH or S or a compound of formula (3) wherein R8 is alkyl or aminoalkyl R9 is hydrogen, alkyl or optionally substituted phenyl or, a compound of formula (4) wherein Z is O, S, CH2, CHR13 or a bond R10, R11, R12 and R13 are each independently alkyl or hydrogen or, a compound of formula (5) wherein R14 is alkyl and the pharmaceutic

Abstract: The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.

Abstract: Novel stilbenoid compounds and their prodrug forms are disclosed, which serve as potent vascular targeting agents useful for the treatment of solid tumor cancers and other diseases associated with unwanted neovascularization. The novel stilbenoid compounds are tubulin-binding stilbenoid analogs structurally related to combretastatin A-1 and combretastatin A-4. The prodrug forms serve as potent vascular targeting agents (VTAs) useful for the treatment of solid tumor cancers and diseases associated with retinal neovascularization.

Abstract: A diverse set of tubulin binding ligands have been discovered which are structurally characterized, in a general sense, by a semi-rigid molecular framework capable of maintaining aryl—aryl, pseudo pi stacking distances appropriate for molecular recognition of tubulin. In phenolic or amino form, these ligands may be further functionalized to prepare phosphate esters, phosphate salts, and phosphoramidates capable of demonstrating selective targeting and destruction of tumor cell vasculature.

Abstract: A chemiluminescent assays for the determination of the presence or amount of a biopolymer in bound assays using 1,2-dioxetanes in connection with AttoPhos™ as chemiluminescent substrates for enzyme-labeled targets or probes is provided. Further disclosed is a kit for conducting a bioassay for the presence or concentration of a biopolymer comprising a) an enzyme complex; b) a 1,2-dioxetane; and c) AttoPhos™.

Abstract: Diphenylheteroalkyl derivatives of the formula I ##STR1## where A and R.sup.1 -R.sup.6 have the meanings specified in the description, and the preparation thereof are described.The substances are suitable for controlling diseases and as cosmetic agents.

Abstract: A process for the preparation of alkyl arylphosphinites of the formula (I) ##STR1## in which R.sup.1 is (C.sub.1 -C.sub.16)-alkyl, cyclohexyl, cyclopentyl, arylwhich can also be substituted by halogen, (C.sub.1 -C.sub.6)-alkoxy groupsR.sup.2 is aryl which can also be substituted by halogen, (C.sub.1 -C.sub.6)-alkyl, (C.sub.1 -C.sub.6)-alkoxy groups, where R.sup.1 and R.sup.2 together with the phosphorous atom can also form a ring andR.sup.3 is (C.sub.1 -C.sub.4)-alkyl, which comprises reacting halo(aryl) phosphines of the formula (II) ##STR2## in which R.sup.1, R.sup.2 have the meaning given above and X is halogen, with ammonia-containing alcohols of the formula (III)R.sup.3 OH (III)in which R.sup.3 has the meaning given above.

Abstract: There are disclosed novel hydroquinone derivatives of the formula: ##STR1## The derivatives of the formula (I) have various pharmacological activities such as antioxidation in living bodies and are useful as medicaments.

Abstract: Compounds of the general formula I ##STR1## in which n is 1, 2 or 3 and in which X is oxygen or sulfur, T has the meaning of --S--, --S--S--, --S--S--, --S--S--S--S--, --S--S--S--S--S--, ##STR2## and Y has the meaning of ##STR3## in which Z has the meaning of --H, --COR.sup.13, --COOR.sup.13 or --CONHR.sup.13, and Q has the meaning of oxygen or --NR.sup.0 --, and R.sup.1, R.sup.2, R.sup.0, R.sup.4 and R.sup.13 are as defined in claim 1, with the proviso that the compound of the formula C.sub.2 H.sub.5 --S--CH.sub.2 CH(OH)--P(OC.sub.2 H.sub.5).sub.2 is excepted.The invention also relates to compositions containing the compounds of the formula I and organic materials, for example functional liquids and, in particular, lubricants.

Abstract: Certain compounds have been synthesized and found to be effective inhibitors of phospholipase A.sub.2 (PLA.sub.2), and thereby useful in the treatment of intestinal cholesterol absorption and the disease states arising therefrom, such as hypercholesterolemia and coronary artery disease.

Abstract: Tetrakis(2,4-di-tert-butyl-5-methylphenyl)-4,4'-biphenylenediphosphonite, stabilizers for organic materials, which contain said compound, and stabilized organic materials containing said compound as a stabilizer. The tetrakis(2,4-di-tert-butyl-5-methylphenyl)-4,4'-biphenylenediphosphonite has particularly superior hydrolysis resistance, and is characterized in that it has superior storage stability due to its scarce hygroscopicity. It can be purified and handled easily since it is in a powder form, and it shows less volatility at high temperatures. By using the compound of the present invention as a stabilizer for organic materials, extremely useful organic materials imparted with superior processing stability, heat resistance and resistance to oxidative degradation can be provided.

Abstract: Aryl phosphinites of the formula (I) ##STR1## can be prepared in a simple manner and in high yields by reacting 2,4-di-tert.-butylphenylphosphonous dihalides with alkyl- or arylmagnesium bromides or alkyl- or arylmagnesium chlorides.Aryl phosphinites serve for the preparation of secondary phosphine oxides which are used as starting materials for the preparation of phosphine ligands in catalyst systems.

Abstract: Aryl esters of phosphonous halides of the formula I ##STR1## in which R' is a phenyl or benzyl radical which bears 1 to 3 substituents, .alpha.-methylbenzyl, .alpha., .alpha.-dimethylbenzyl, naphthyl or a naphthyl radical bearing 1 to 5 substituents, where the substituents are identical or different and are a non-aromatic hydrocarbon radical, an alkoxy radical or alkylthio radical each having 1 to 8 carbon atoms, aryl or aryloxy each having 6 to 10 carbon atoms or halogen having an atomic number from 9 to 35,R.sup.2 is a non-aromatic hydrocarbon radical having 1 to 18 carbon atoms, aryl, arylmethyl, arylethyl or arylisopropyl, where each aryl contains 6 to 10 carbon atoms,R.sup.3 is hydrogen or one of the groups mentioned under R.sup.2, andX is chlorine or bromine.The invention further relates to a process for the preparation of aryl esters of phosphonous halides of the formula I.

Abstract: Diarylphosphinous acid aryl esters are made by the disclosed process. These compounds are useful for stabilizing plastics, in particular polymerization plastics, and hence can be incorporated into a plastic molding composition.

Abstract: Compounds which are useful as inhibitors of cholesterol biosynthesis and thus as hypocholesterolemic agents are provided which have the structure ##STR1## wherein R is OH, or salts thereof or lower alkoxy;R.sup.x is H or alkyl;X is --CH.sub.2 --, --CH.sub.2 --CH.sub.2 --, --CH.dbd.CH--, --C.tbd.C--, --CH.sub.2 CH.sub.2 CH.sub.2 -- or --CH.sub.2 O-- (where O is linked to Z);Z is a hydrophobic anchor, such as ##STR2## wherein the dotted lines represent optional double bonds.

Abstract: The use of a compound of the formula I ##STR1## in which V is an alkyl group, fluorine, chlorine, bromine, or iodine, n is an integer from 1 to 5, W is an alkyl, alkenyl, alkynyl or alkoxy group, cyanide, nitro, carboxyl, hydrogen or a cycloalkyl, aryl, aralkyl or carboalkoxy group, R.sup.1 and R.sup.2 are an alkyl, alkenyl, alkynyl, cycloalkyl or halogenoalkyl group, sodium, potassium, calcium, magnesium, aluminum, lithium, ammonium, triethylammonium or hydrogen, R.sup.1 and R.sup.2 together form a cyclic diester, R.sup.3 and R.sup.4 are an alkyl, alkenyl, alkynyl, carboalkoxy, cycloalkyl or alkoxy group, hydrogen, fluorine, chlorine, bromine or iodine and X, Y and Z are oxygen or sulfur, for the treatment of diseases caused by DNA viruses or RNA viruses is described.

Abstract: An alkenoic acid derivative of the formula ##STR1## in which X and Y are identical or different and represent sulfur, sulfoxide, sulfone, an alkylene chain, --SCH.sub.2 --, or oxygen or a direct bond,W represents --CH.dbd.CH--or --CH.sub.2 --CH.sub.2 --,o represents a number 1 to 5,A and B are identical or different and represent carboxyl, carboxymethylene, tetrazolyl or tetrazolylmethylene, or --CO.sub.2 R.sup.9 or --CH.sub.2 CO.sub.2 R.sup.9 or --CONR.sup.10 R.sup.11 or nitrilen represents a number 1 to 10,m represents a number 0 to 7,T and Z are identical or different and represent oxygen or a direct bond andR.sup.2, R.sup.3, R.sup.8 are identical or different and represent hydrogen, alkyl, alkoxy, halogen, trifluoromethyl, trifluoromethoxy, cyano or nitro andR.sup.9 is lower alkyl and R.sup.10 and R.sup.11 are hydrogen, lower alkyl, alkylsulfonyl or arylsulfonyl or together are an alkylene chain to form a ringand pharmaceutically acceptable salts thereof.

Abstract: Novel angiotensin II receptor antagonists of the formula ##STR1## wherein X, X.sub.1, X.sub.2, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined herein, are disclosed. These compounds are useful, for example, in the treatment of hypertension, congestive heart failure and cardiac hypertrophy.

Abstract: This invention relates to a process for the preparation of insecticidally active compounds and to novel styrene derivatives useful as intermediates therein.

Abstract: Herbicidal (hetero)aryloxynaphthalene derivatives of the formula ##STR1## in which X is N or --C--R.sup.5,R.sup.1, R.sup.2, R.sup.4 and R.sup.5 are hydrogen or halogen or R.sup.1 may be cyano or trifluoromethyl,R.sup.3 is halogen, trifluoromethyl, trifluoromethoxy, trifluoromethylthio or trifluoromethylsulphonyl,Y is optionally halogen-substituted alkanediyl or alkenediyl, andZ is CN or --CC--Z', whereZ' is halogen, hydroxyl, amine, alkoxy, or the like.Intermediates of the formula ##STR2## are also new.

Abstract: Novel carboxamide compounds represented by the general formula (I) possess excellent activities for lowering lipids and thus they are useful as agents for treating and preventing various diseases (hyperlipidemia) such as hypercholesterolemia, hypertriglyceridemia, hyperphospholipidemia, hyperlipacidemia, and the like.

Abstract: Compounds having the formula: ##STR1## wherein T is a polycycloalkylidene group (e.g., adamant-2-ylidene); R is a C.sub.1-20 alkyl, aralkyl or cycloalkyl group; and Y is a fluorescent chromophore (e.g., m-phenylene), produced by reacting a compound having the formula: ##STR2## with an R-ylating agent (e.g., R.sub.2 SO.sub.4) in the presence of an alkali metal alkoxide in a polar aprotic solvent. Also, compounds having the formula: ##STR3## are produced by reacting a compound having the formula: ##STR4## wherein X is an electronegative leaving group (e.g., a halogen anion such as chloride ion) in the presence of a Lewis base (e.g., a trialkyl-amine) dissolved in an aprotic organic solvent (e.g., benzene or toluene). Also, compounds having the formula ##STR5## are produced by reacting a compound of the formula ##STR6## with a tetra-O-acylated-O-hexopyranoside halide, then hydrolyzing off the protective acyl groups.

Abstract: Novel bis-S-alkylbenzene derivatives capable of inhibiting lipoxygenase, inparticular, 5-lipoxygenase are disclosed. It is expected that the compounds, which are hardly metabolized in vivo, are highly useful in the treatment and/or prevention of various diseases, including allergic diseases such as asthma, inflammation, myocardial infarction, nephritis, scabies and gout.

Abstract: Compounds having the formula ##STR1## R.sub.1 is hydrogen, benzyl or alkanoyl, X is C.sub.2-4 alkylene; andZ-W is alkyl, phenylalkyl or pyridylalkyl which can have an oxygen atom as part of the alkyl chain and their use as CNS agents, antidiarrheals and antiemetics. Processes for their preparation and intermediates therefor are described.

Abstract: A process for regioselectively preparing phosphorylated cyclitols, in particular phosphorylated inositols such as myo-inositol 1,4,5-tris(phosphate) and myo-inositol 1,3,4,5-tetrakis(phosphate). Novel cyclitols produced by means of this process are also described.

Abstract: Certain phenyl and N-heterocyclic phosphorothioates and phosphates are prepared by the reaction of an appropriate alkali metal or alkaline earth metal -O-phenyl or N-heterocyclic compound with an appropriate phosphorochloridate or phosphorochloridothioate under alkaline conditions in a liquid reaction medium and in the presence of a tertiary amine catalyst and a nonionic surfactant having a HLB Value of from about 2.5 to about 20 or more.

Abstract: Certain phenyl and N-heterocyclic phosphorothioates and phosphonothioates and phosphates are prepared by the reaction of an appropriate alkali metal or alkaline earth metal --0-phenyl or N-heterocyclic compound with an appropriate phosphorochloridate, phosphorochloridothioate, phosphonochloridate or phosphonochloridothioate under alkaline conditions in the presence of a tertiary amine catalyst and a nonionic surfactant having an HLB Value of from about 1 to about 20, preferably about 5 to 15, in a two-phase system, one phase being primarily the phosphorate or phosphonate reactant and a complex thereof with the tertiary amine catalyst and the other phase being an aqueous reaction medium comprising water, a buffer system, and the alkali metal or alkaline earth metal-O-phenyl or --O-N-heterocyclic compound, in the substantial or complete absence of an organic solvent the aqueous reaction medium being maintained at pH about 10 to 12 by the buffer system.

Abstract: Compounds having the formula ##STR1## wherein ##STR2## R.sub.1 is hydrogen, benzyl or alkanoyl, X is C.sub.2-4 alkylene; andZ-W is alkyl, phenylalkyl or pyridylalkyl which can have an oxygen atom as part of the alkyl chain and their use as CNS agents, antidiarrheals and antiemetics. Processes for their preparation and intermediates therefor are described.

Abstract: Disclosed are novel phosphoric ester derivatives of the formula (I): ##STR1## wherein R.sup.1 and R.sup.2 each represents a lower alkyl group; R.sup.3 represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group or a lower alkylthio group; X.sup.1 and X.sup.2 are the same or different and each represents a hydrogen atom or a halogen atom; and Y represents an oxygen atom or a sulfur atom, and insecticidal and miticidal compositions containing said derivatives.

Abstract: Compounds having the formula ##STR1## in which R.sub.1 is methyl or ethyl; R.sub.2 is C.sub.1 -C.sub.6 alkyl; R.sub.3 is halogen, C.sub.1 -C.sub.4 alkyl, trifluoromethyl, thio-(C.sub.1 -C.sub.4 alkyl) or phenoxy, and n is 0, 1 or 2; provided that if R.sub.2 is methyl, then R.sub.1 is methyl, are insecticides.

Abstract: A vinylbenzyl phosphate of the formula I ##STR1## where A, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 have the meanings stated in the description, and their preparation are described. The substances are useful for the treatment of disorders.

Abstract: Phosphates of the formula ##STR1## where R.sup.1 is alkyl of not more than 3 carbon atoms, R.sup.2 is alkoxy, alkylthio or alkylamino each of which has a straight-chain or branched alkyl substituent of not more than 5 carbon atoms, Y.sup.1 and Y.sup.2 independently of one another are each hydrogen, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -alkoxy or halogen, and X is O or S, a process for their manufacture, and their use as insecticides and acaricides.

Abstract: The invention relates to new organic phosphoric acid esters represented by the general formula ##STR1## wherein X represents O, S or NH,Y represents O or S,R.sup.1 represents a lower alkyl group,R.sup.2 represents a lower alkyl group or a lower alkoxy-lower alkyl group,R.sup.3 represents a fluoro-substituted lower alkyl group,Z represents a lower alkyl group, a lower alkoxy group or a halogen atom, andn represents 0 or 2,which can be used as pesticidally active agents.

Abstract: Dihalovinylphenyl phosphates of the formula I ##STR1## where A and B are each halogen or trihaloalkyl, X is oxygen or sulfur, Y and Z are each oxygen, sulfur or --NH--, R.sup.1 is alkyl, R.sup.2 is alkyl, haloalkyl, alkoxyalkyl or alkylthioalkyl, and R.sup.3, R.sup.4 and R.sup.5 independently of one another are each hydrogen, halogen, nitro, alkyl, cyano, alkoxy, alkoxyalkoxy, alkylthioalkylthio, alkoxyalkyl, alkylthioalkyl, alkylthio, trihaloalkyl or trihaloalkoxy, and pesticides containing these compounds.